Berlin (pta/01.08.2022/17:00 UTC+2)
TELES AG (ISIN DE000A289B07 / WKN A289B0) continues to grow significantly against the market. The pharmaceutical supply segment is proving to be the strongest growth driver.
The TELES Group achieved sales revenues of EUR 39.5 million (previous year: EUR 1,224 thousand). The operating cash flow grew to EUR 741 thousand (previous year: EUR -70 thousand). Both are an expression of the great demand for the company's products.
The earnings situation of the TELES Group improved significantly in the first half of 2022 compared to the same period of the previous year. Gross profit tripled to EUR 1.3 million (previous year: EUR 419 thousand) and thus exceeded the forecast.
The investment of EUR 721,000 primarily includes expenses for ongoing automation at EURO RX Arzneimittel GmbH. As of June 30, 2022, the financial resources were EUR 1.3 million (previous year: EUR 644 thousand) and offer a solid basis for further growth.
Personnel expenses increased by 121% to EUR 1,651 thousand (previous year: EUR 746 thousand) due to the integration of EURO RX Arzneimittel GmbH. Depreciation was EUR 197 thousand (previous year: EUR 89 thousand). Other operating income was EUR 69 thousand (previous year: EUR 34 thousand). With the increase in other operating expenses of EUR 916k (prior year: EUR 209k), EBITDA was EUR 244k (prior year: EUR -10k) and the consolidated result was EUR -234k (prior year: EUR -112k).
The balance sheet total of TELES increased by EUR 10.3 million compared to the previous year due to the larger current assets of EUR 10.0 million.
Chief Executive Officer
|Contact Person:||Oliver Olbrich|
|Phone:||+49 30 399 28 00|
|Stock Exchange(s):||Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart|